Home > Journals > Minerva Oftalmologica > Past Issues > Minerva Oftalmologica 2016 March;58(1) > Minerva Oftalmologica 2016 March;58(1):1-5

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA OFTALMOLOGICA

A Journal on Ophthalmology


eTOC

 

ORIGINAL ARTICLES  


Minerva Oftalmologica 2016 March;58(1):1-5

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

The role of a novel oral curcumin delivery form (Meriva®) dietary supplementation in meibomian gland dysfunction

Fabio MAZZOLANI 1, Stefano TOGNI 2, Luca GIACOMELLI 3, Federico FRANCESCHI 2

1 Private Ophthalmology Practitioner, Milan, Italy; 2 Indena S.p.A., Milan, Italy; 3 Department of Surgical Sciences and Integrated Diagnostics, School of Medicine, University of Genoa, Genoa, Italy


FULL TEXT  


BACKGROUND: Dysfunction of meibomian gland (MGD) is among the most frequent causes of ocular discomfort. Inflammation plays a major role in MGD, and evidence of the antioxidant-inflammatory properties of oral curcumin suggests its use as a treatment for MGD. We analyzed the effectiveness of a novel oral curcumin delivery form (Meriva®) in improving tear stability and in reducing inflammatory symptoms and signs due to MGD.
METHODS: We enrolled 12 patients, over a 3-month period, who presented with symptomatic MGD and tear instability (defined as tear breakup time [TBUT] <10 seconds). We performed the following tests: TBUT, Quality of life (QOL) Test, interpalpebral corneal dye staining and evaluation of lid margin inflammation. All patients received the oral curcumin delivery form at 1 g/day.
RESULTS: After three months, TBUT, QOL Test, interpalpebral corneal dye staining and lid margin inflammation improved from baseline values.
CONCLUSIONS: Meriva®, a novel curcumin delivery form, may be beneficial in the treatment of MGD, mainly by improving tear stability and decreasing secondary superficial ocular inflammation.

top of page

Publication History

Cite this article as

Corresponding author e-mail